Abstract
This study retrospectively calculated the LabPS score (laboratory parameters + performance status) in patients with small-cell lung cancer (SCLC) and non-SCLC who were treated with curative radiotherapy. The score was derived from pretreatment laboratory parameters – including hemoglobin level, platelet count, serum lactate dehydrogenase, serum albumin, and serum C-reactive protein – and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The primary aim was to investigate the association between the LabPS score and overall survival (OS). The LabPS score was calculated retrospectively by reviewing pretreatment routine complete blood counts, biochemistry results, and ECOG PS of patients diagnosed with lung cancer and treated with radiotherapy. Patients who underwent radiotherapy with curative intent were selected. Patients with metastatic lung cancer and ECOG PS ≥ 3 were excluded. The primary endpoint was determined as OS. When LabPS scores were evaluated using receiver operating characteristic curve analysis, patients were classified into 2 prognostic groups: “favorable” (≤1) and “unfavorable” (>1), with an area under the curve corresponding to a 95% confidence interval: 0.654 to 0.806. Patients were stratified according to both their TNM stage and LabPS score, and survival analyses were subsequently conducted. These analyses demonstrated that patients with early-stage disease and a favorable LabPS score had significantly longer OS. In this study, the LabPS score successfully stratified patients with SCLC and non-SCLC into prognostic groups, demonstrating significant survival differences between the favorable and unfavorable categories. These findings suggest that the LabPS score has potential for survival prediction. Because the LabPS score can be easily calculated using routine laboratory tests in combination with PS, it has the potential to serve as a practical and cost-effective tool in daily oncology practice, pending further validation in larger, prospective cohorts. If validated in future studies, this score may potentially assist in clinical decision-making, including the timing of chemoradiotherapy, radiation dose optimization, and the development of personalized treatment plans.
Keywords: LabPS score, lung cancer, radiotherapy
1. Introduction
Lung cancer is one of the most significant causes of cancer-related deaths worldwide and has the highest mortality rates among both men and women. The most common types of lung cancer are non-small-cell lung carcinoma and small-cell lung carcinoma. Non-small-cell lung carcinoma is more common and has a relatively slower course, while small-cell lung carcinoma is rarer but tends to progress rapidly. Treatment options include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies.
This study retrospectively calculated the LabPS score (laboratory parameters + performance status) in patients with small-cell lung cancer (SCLC) and non-SCLC (NSCLC) who were treated with curative radiotherapy. The score was based on pretreatment laboratory parameters, including hemoglobin level, platelet count, serum lactate dehydrogenase (LDH) level, serum albumin level, and serum C-reactive protein (CRP) level, as well as performance status (PS). The study aimed to investigate the relationship between the LabPS score and overall survival (OS) duration.
This study sought to determine the relationship between the LabPS score, calculated using pretreatment serum biochemistry and hemogram tests, as well as PS during treatment and survival duration in patients with small-cell lung carcinoma and non-small-cell lung carcinoma treated with chemoradiotherapy or radiotherapy alone. The evaluation of this relationship was based on the knowledge that high serum LDH levels are important indicators of poor prognosis and are associated with treatment resistance.[1] Furthermore, serum albumin levels, which reflect nutritional status and can be used as a survival marker, were also included in this parameter.[2,3] CRP is a typical acute-phase protein primarily synthesized by the liver and is one of the most common biochemical markers of systemic inflammation. An increase in serum CRP levels has been considered a prognostic indicator in many malignancies, such as lung cancer, breast cancer, and colorectal cancer.[4]
Additionally, hemoglobin and platelet levels have also been reported to be useful as prognostic factors in cancer patients. In this context, this study investigated the usability of the LabPS score, which has been reported as a successful marker for predicting survival in patients with brain metastases, in lung cancer patients undergoing curative treatment. Furthermore, the Eastern Cooperative Oncology Group performance status (ECOG PS) remains a reliable and relevant prognostic factor, holding significant importance across various tumor types, including advanced NSCLC.[5–8] Scoring systems such as modified Glasgow prognostic score, Naples Prognostic Score, and Royal Marsden Hospital score are used worldwide in cancer progression, treatment response, and cancer survival.[9–11] Differing from these scoring systems, we aimed to investigate the contribution of the ECOG PS when calculating the LabPS score. Furthermore, we aimed to strengthen survival prediction by adding multiple laboratory parameters that are already checked in routine clinical practice and are known to have separate effects on survival estimation.
The primary endpoint was determined as OS. Local or regional progression, regional recurrence, and distant metastasis development were defined as secondary outcomes. The LabPS score could also enable the efficient use of resources in clinical practice.
2. Materials and methods
2.1. Inclusion and exclusion criteria
All patients were selected from cases that received radiotherapy with a curative (definitive) intent. Patients with advanced metastatic lung cancer, those who received only palliative radiotherapy, and those with an ECOG performance score of 3 or higher were excluded from the study. Since the analyzed laboratory tests were evaluated retrospectively, no new blood samples were taken from the patients. The clinical stages of the patients were determined by the TNM (Tumor, Node, Metastasis classification) staging system.
A total of 1097 patients (850 with NSCLC and 247 with SCLC) who received treatment at our institution between 2012 and 2019 were retrospectively evaluated. Patients were excluded based on the following criteria: 623 patients due to metastatic disease; 84 patients due to an ECOG PS of ≥3; 128 patients due to missing laboratory data; and 123 patients due to loss to follow-up, which prevented us from determining their survival status. Consequently, 139 patients with complete datasets were included in the final analysis, as detailed in the flowchart (Fig. 1).
Figure 1.
Study flow diagram and inclusion/exclusion summary. ECOG = Eastern Cooperative Oncology Group, NSCLC = non-small-cell lung cancer, SCLC = small-cell lung cancer.
2.2. LabPS score calculation
The LabPS score was calculated by retrospectively evaluating the routine pretreatment complete blood count and biochemistry tests, as well as the ECOG performance scores determined during examination, for lung cancer patients who received radiotherapy in our clinic between 2012 and 2019. No control group was included in the study. The LabPS score was calculated according to the method used by Berghoff et al.[5] For the score calculation, 1 point was added for each of the following: serum LDH and CRP levels being above the laboratory reference ranges. Additionally, 0.5 points were added for each of the following: hemoglobin, platelet, and serum albumin levels being below the laboratory reference ranges. No extra points were given to patients with a performance score of 0 or 1, but an additional 0.5 points were included for patients with a performance score of 2. The lowest possible total score was 0 points when all laboratory parameters were within normal limits and the performance score was 0 or 1. The highest possible total score was 4 points when all parameters were abnormal and the performance score was 2 (Table 1). The numerical values of the laboratory parameters and performance score were summed to create an individual LabPS score. The scoring system is schematically shown in Table 1.
Table 1.
LabPS scoring system.
| Parameter | 0 point | 0.5 points | 1 point |
|---|---|---|---|
| Hemoglobin | Reference range or above reference value | Below reference value | |
| Platelet count | Reference range or above reference value | Below reference value | |
| Albumin | In reference range | Below reference value | |
| LDH | In reference range | Above reference value | |
| CRP | In reference range | Above reference value | |
| ECOG PS | ECOG 0–1 | ECOG 2 |
CRP = C-reactive protein, ECOG PS = Eastern Cooperative Oncology Group performance status, LabPS = laboratory parameters + performance status, LDH = lactate dehydrogenase.
2.3. Parameters and evaluation criteria used in LabPS scoring
When calculating the LabPS score, the patients’ laboratory findings were evaluated based on the reference ranges for the years they were treated. The scoring was performed according to the following criteria:
CRP: The upper limit for CRP measured by the turbidimetric method was taken as 5 mg/L. If the patient’s CRP level was above this limit, 1 point was added to the score.
Hemoglobin, platelet count, and albumin: If the hemoglobin (using separate limits for men and women), platelet count, and albumin values were below the accepted lower limits, 0.5 points were added.
LDH: If the LDH value was above the accepted upper limits, 1 point was added to the LabPS score.
ECOG performance score: No extra points were given to patients with an ECOG performance score of 0 or 1. For patients with an ECOG score of 2, 0.5 points were added. Patients with an ECOG performance score of 3 or higher were not included in the study.
LabPS score was calculated as follows:
2.4. Population-based evaluation (smokers and occupational groups)
Patients were classified according to their smoking status as those who never smoked, those who smoked <20 pack-years, those who smoked 20 to 40 pack-years, and those who smoked 40 pack-years or more. Furthermore, they were categorized as mining workers, iron-steel workers, construction sector workers, and other occupational groups.
The classification of scores, as determined by receiver operating characteristic analyses, designated a score as “favorable” when it was equal to or <1 and “unfavorable” when it was >1, with an area under the curve corresponding to a 95% confidence interval (CI): 0.654 to 0.806.
In this study, cases with incomplete laboratory data for any LabPS component and treatment or death time were excluded from the analysis using a complete-case analysis approach. This ensures consistency and prevents bias from imputed values.
2.5. Statistical analysis
All statistical analyses were conducted using IBM SPSS Statistics (Version 29.0). Descriptive statistics for continuous variables were expressed as mean ± standard deviation or median (min–maximum), and categorical variables as frequency and percent. Chi-square tests were used for categorical comparisons. Receiver operating characteristic analysis was performed to determine the optimal cutoff for the LabPS score using the Youden index (J = sensitivity + specificity − 1), and the area under the curve with 95% CIs was calculated. Kaplan–Meier survival analyses and log-rank tests were used for univariate comparisons. Multivariate analyses were conducted using the Cox proportional hazards regression model. Before the multivariate analysis, multicollinearity was assessed using variance inflation factors, all below 2.0. Patients with missing data for any of the LabPS parameters or ECOG PS were excluded (complete-case analysis). Hazard ratios and 95% CIs were reported along with P-values, and P < .05 was considered statistically significant.
3. Results
3.1. Patient characteristics
A total of 139 patients were retrospectively reviewed. The majority of these patients were male (132), while 7 were female. The age range was from 40 to 81, with a mean age of 61.67.
The stage distribution of the patients was as follows: 2 patients in stage 1A, 1 patient in stage 1B, 3 patients in stage 2A, 19 patients in stage 2B, 31 patients in stage 3A, 45 patients in stage 3B, and 38 patients in stage 3C. Of the total 139 patients included in the study, 38 had pathological characteristics of SCLC, and 101 had NSCLC. The subtype distribution for the 99 patients with NSCLC was as follows: 36 patients (36.4%) with adenocarcinoma, 60 patients (60.6%) with squamous cell carcinoma, 3 patients (3%) with adenosquamous carcinoma, 1 patient with a malignant epithelial tumor, and 1 patient with NSCLC of an unspecified subtype (Table 2).
Table 2.
Patient characteristics.
| Variables | n (%) |
|---|---|
| Sex | |
| Male | 132 (95) |
| Female | 7 (5) |
| Age (in yr) | |
| Mean | 61.67 |
| Range | 40–81 |
| Treatment | |
| Chemoradiotherapy (CRT) | 131 (94.2) |
| Radiotherapy (RT) | 8 (5.8) |
| Demographics | |
| Primary hypertension | 52 (37.4) |
| Diabetes mellitus | 21 (15.1) |
| Chronic obstructive pulmonary disease | 17 (12.2) |
| Coronary artery disease | 15 (10.8) |
| Hyperlipidemia | 14 (10.1) |
| Benign prostatic hyperplasia | 8 (5.8) |
| Glaucoma | 4 (2.9) |
| Cerebrovascular disease | 4 (2.9) |
| Depression | 3 (2.2) |
| Parkinson disease | 2 (1.4) |
| Rheumatoid arthritis | 1 (0.7) |
3.2. Treatment characteristics and comorbidities
Of the 139 patients included in the study, 131 (94.2%) were treated with chemoradiotherapy, while 8 patients (5.8%) received radiotherapy alone. The reasons for receiving only radiotherapy were determined to be refusal of chemotherapy, being unsuitable for chemotherapy, or a sequential treatment plan. The most common comorbidities observed were primary hypertension in 52 patients (37.4%) and diabetes mellitus in 21 patients (15.1%).
3.3. Smoking status
An analysis of pretreatment patient files revealed that 10 patients (7.2%) had never smoked. The smoking history was as follows: 16 patients (11.5%) had a history of <20 pack-years, 61 patients (43.9%) had a history of 20 to 40 pack-years, and 52 patients (37.4%) had a history of over 40 pack-years (Table 3).
Table 3.
Smoking status.
| Smoking | n (%) |
|---|---|
| Never smoked | 10 (7.2) |
| <20 pack/yr | 16 (11.5) |
| 20–40 pack/yr | 61 (43.9) |
| >40 pack/yr | 52 (37.4) |
| Total patient | 139 (100) |
3.4. Occupational distribution and its relationship with the LabPS score
Since the study was conducted in the province of Zonguldak, which has a large mining population, the patients’ occupations were also evaluated. Accordingly, the relationship between occupational groups and the LabPS score was examined. When all patients were evaluated, it was determined that 51 patients (36.7%) had a profession related to mining, 5 patients (3.6%) had a profession related to the iron and steel industry, and 9 patients (6.5%) worked in the construction sector.
3.5. Impact of LabPS score on survival
The optimal cutoff for the LabPS score was determined as 1.0 using the Youden Index. It was determined that patients with a score of 1 or less demonstrated favorable prognostic characteristics, while those with a score >1 were associated with unfavorable prognostic outcomes. Accordingly, patients with a LabPS score of ≤1 were classified as “favorable,” and those with a score of >1 were classified as “unfavorable” prognostic groups. The median survival time for the favorable LabPS score group (63 months) was significantly longer than for the unfavorable group (23 months). This difference was statistically significant (95% CIs: 39.56–86.45 vs 14.92–31.08; P: .001). The relevant survival curves are presented in the graph below (Fig. 2).
Figure 2.
Kaplan–Meier overall survival curves by LabPS score in patients receiving curative radiotherapy for lung cancer. LabPS = laboratory parameters + performance status.
The clinical stages of the patients, as determined by the TNM staging system, were also included in the study, and their relationship with the LabPS score was analyzed. However, no statistically significant relationship was found between the LabPS score and disease stage (P = .115). Due to the uneven gender distribution (imbalance in the number of male and female patients), no subgroup analyses based on gender were performed. Patients were categorized based on both their TNM stages and LabPS scores, and survival analyses were conducted. These evaluations determined that the survival duration of patients in the low-stage and “favorable” LabPS group was significantly longer, while the survival of patients with a high stage and “unfavorable” LabPS score was significantly lower (P < .001; Fig. 3).
Figure 3.
Kaplan–Meier survival analysis stratified by the relationship between disease stage and LabPS score. The curves demonstrate the cumulative survival probability for patients categorized into 4 subgroups: stage 1 to 2 with favorable LabPS; stage 1 to 2 with unfavorable LabPS; stage 3A and above with favorable LabPS; stage 3A and above with unfavorable LabPS. LabPS = laboratory parameters + performance status.
The comprehensive survival analysis demonstrated that the LabPS score is an extremely potent prognostic factor, with the survival distributions across the 8 score categories being highly statistically significant (Log-rank χ2 = 106.042, P < .001), as median survival time decreased sharply from 111 months (LabPS 0.0) to 5 months (LabPS 3.5), confirming a drastic prognostic gradient where survival significantly deteriorates with increasing score levels. The relevant survival curves are presented in the graph below (Fig. 4).
Figure 4.
Kaplan–Meier survival curves based on LabPS scores. The graph illustrates the cumulative survival probability over time (months) for patients stratified by their LabPS scores (ranging from 0 to 3.5). LabPS = laboratory parameters + performance status.
Each component of the LabPS score was grouped according to its assigned score and analyzed separately using the Kaplan–Meier method to better understand its individual contribution to survival.
No statistically significant difference was found between the median survival time of the hemoglobin value “below the target” group (37 months, 95% CI: 19.51–54.49) and the “target range” group (42 months, 95% CI: 26.42–57.58; P = .4).
No statistically significant difference was found between the median survival time of the platelet value “below the target” group (46 months, 95% CI: 0.0–104.67) and the “target range” group (42 months, 95% CI: 29.76–54.24; P = .427).
Patients with high serum LDH levels experienced a significantly shorter median survival time (26 months, 95% CI: 11.91–40.09) compared with those with low/normal LDH levels (median 51 months, 95% CI: 38.70–63.29). The difference in survival distributions was highly statistically significant (log-rank χ2 = 8.82, P = .003). Patients with high CRP levels experienced a significantly shorter median OS time (27 months, 95% CI: 19.56–34.44) compared with those with low/normal CRP levels (median 76 months, 95% CI: 18.66–133.34). The difference in survival distributions was highly statistically significant (log-rank χ2 = 16.420, P < .001), supporting LDH and CRP as prognostic factors.
Another important variable contributing to the LabPS score, the ECOG PS, was also examined. Patients with poor ECOG PS (ECOG PS: 2) experienced a drastically shorter median survival time (15 months, 95% CI: 11.98–18.02) compared with those with good PS (ECOG PS: 0–1; median: 55; 95% CI: 38.06–71.95). The difference in survival distributions was extremely statistically significant (log-rank χ2 = 55.858, P < .001).
In the univariate analysis, low albumin levels were associated with a significantly shorter median survival time of 20 months (95% CI: 8.24–31.76) compared with high/normal levels of 46 months (95% CI: 34.29–57.70; P = .017). However, albumin did not retain its significance in the multivariate analysis (P = .795), suggesting that it is not an independent prognostic factor when other variables are accounted for.
Both univariate and multivariate Cox regression analyses for each of these parameters supported the Kaplan–Meier analysis results, confirming that elevated LDH, elevated CRP, and poor ECOG PS were independent predictor factors of survival (Table 4).
Table 4.
Univariate and multivariate Cox regression analysis.
| HR (95% CI) | P value | HR (95% CI) | P value | |
|---|---|---|---|---|
| Hemoglobin | 1.18 (0.80–1.72) | .404 | 1.09 (0.71–1.65) | .705 |
| Platelet | 0.76 (0.38–1.51) | .432 | 0.98 (0.47–2.03) | .951 |
| LDH | 2.04 (1.26–3.32) | .004 | 2.34 (1.36–4.03) | .002 |
| Albumin | 1.93 (1.11–3.34) | .020 | 1.09 (0.58–2.05) | .795 |
| CRP | 2.37 (1.54–3.65) | <.001 | 1.84 (1.13–3.00) | .015 |
| PS | 4.43 (2.90–6.78) | <.001 | 3.80 (2.38–6.05) | <.001 |
| Smoking (1 vs 0) | 1.14 (0.43–3.05) | .791 | 1.32 (0.47–3.71) | .603 |
| Smoking (2 vs 0) | 1.45 (0.62–3.39) | .396 | 1.44 (0.57–3.61) | .442 |
| Smoking (3 vs 0) | 1.64 (0.70–3.86) | .259 | 1.77 (0.72–4.35) | .210 |
| Occupation (1 vs 0) | 1.06 (0.71–1.58) | .780 | 1.08 (0.71–1.65) | .726 |
| Occupation (2 vs 0) | 0.42 (0.10–1.71) | .224 | 0.54 (0.13–2.27) | .398 |
| Occupation (3 vs 0) | 0.63 (0.25–1.56) | .314 | 0.82 (0.32–2.09) | .682 |
All laboratory parameters were dichotomized based on institutional reference ranges as follows: low hemoglobin (male < 13 g/dL, female < 11.7 g/dL), low platelet (<150 × 103/μL), low albumin (<35 g/L), high LDH (>214 U/L), and high CRP (>5 mg/L).
Smoking (0): never smoked, smoking (1): <20 pack/year smoking history, smoking (2): 20 to 40 pack/year smoking history, and smoking (3): >40 pack/year smoking history; occupation (0): other professions, occupation (1): coal miner, occupation (2): iron-steel related profession, and occupation (3): construction related profession.
CI = confidence interval, CRP = C-reactive protein, HR = hazard ratio, LDH = lactate dehydrogenase, PS = performance status.
3.6. Secondary outcome analysis
The analysis of the LabPS score’s impact on long-term outcomes, specifically progression-free survival (PFS), recurrence-free survival (RFS), and metastasis-free survival (MFS), revealed a consistent pattern across all three secondary endpoints.
While the favorable LabPS score group exhibited a numerically longer mean RFS of 120.1 months (95% CI: 107.80–132.40; median not reached) compared with the unfavorable group (88.87; 95% CI: 74.05–103.68; median: 94.0 months), the log-rank test indicated no statistically significant difference in RFS distributions between the 2 groups (P = .067).
Despite the favorable LabPS score group exhibiting a numerically longer mean PFS of 132.46 months (95% CI: 122.92–142.00; median not reached) compared with the unfavorable group (111.00; 95% CI: 100.54–121.47; median not reached), the log-rank test (Mantel–Cox) indicated no statistically significant difference in PFS distributions between the 2 groups (P = .737).
While the favorable LabPS score group consistently exhibited numerically longer mean MFS times of 117.61 months (95% CI: 104.95–130.26; median not reached) compared with the unfavorable group (MFS mean: 99.97 months; 95% CI: 87.32–112.62; median not reached), the difference in MFS distributions between the 2 score groups did not reach statistical significance according to the log-rank test (P = .691). This suggests that while a favorable score is associated with a numerical trend toward better prognosis in secondary outcomes, the difference between the survival curves is not statistically robust enough in this specific cohort to reject the null hypothesis of equality.
4. Discussion
By evaluating all the parameters used to create the LabPS score separately, the aim was to gain a clearer understanding of how their contributions to the score affect survival. Anemia has long been considered an important predictor of worse long-term survival in oncology patients.[7] However, in this study, the points given based on hemoglobin and platelet levels were not observed to have a significant effect on survival. This should not be interpreted as an indication that these parameters lack prognostic importance but rather as a result of insufficient statistical power due to the limited sample size. This study also has limitations, including disadvantages inherent to the retrospective design, lack of cohort diversity (single-center cohort), and lack of external validation. Furthermore, it is thought that a simple 2-group comparison based solely on whether laboratory values are below or above the reference range may not sufficiently reflect the clinical effect of these parameters. For example, even if hemoglobin and platelet values are within normal limits, the functionality of these cells may be impaired in the presence of systemic diseases like cancer. Therefore, when evaluating the effect of these parameters on survival, patient-specific pathophysiological conditions should also be considered.
The contribution of LDH with 1 point to the score demonstrates the significant weight of this parameter in the score. An increase in LDH levels is often associated with the inflammatory response seen in malignancies and is considered an indicator of poor prognosis.[1,12] In our study, patients with high pretreatment LDH levels were found to have a significantly shorter survival time. Given that LDH is a potential marker for both prognosis and predicting treatment response, it is believed that its inclusion in the LabPS score increases confidence in the score.[1,12] Similarly, high CRP levels were found to contribute to the score, providing prognostic value. Previous studies have shown that CRP can be used to predict survival, especially in early-stage lung cancer.[13] In the current study, high CRP levels were also observed to negatively affect survival. This can be explained by the fact that CRP increases with tumor burden.[14] However, it should be considered that acute-phase reactants like CRP can also be elevated due to nonmalignant causes, such as infections. Therefore, attributing high CRP levels solely to malignancy could lead to misinterpretation.
The patient’s PS is a key determinant of their participation in, compliance with, and response to treatment. ECOG PS is a practical and easy-to-use scoring system in the clinic. In NSCLC patients, ECOG PS is considered an independent prognostic factor.[8] However, it should be noted that PS can also be related to the patient’s other existing comorbidities and does not solely reflect performance related to malignancy. From a broad perspective, ECOG PS is a parameter with prognostic importance, and since the presence of comorbidities also negatively affects survival, it remains a reliable assessment. ECOG PS is the only parameter in the LabPS score that is assessed by the physician’s eye, which is why its contribution to the score was determined to be low compared with the sum of the other laboratory parameters’ points.
It should be remembered that all these parameters can represent more than 1 clinical condition in the context of a differential diagnosis. Therefore, using these biomarkers and PS as standalone prognostic tools may provide less reliable results than evaluating them within a combined scoring system. In this context, it is thought that the multi-parametric nature of the LabPS score increases its power to predict survival.
5. Conclusion
Within the scope of this study, the LabPS score demonstrated significant differences in survival between the “favorable” and “unfavorable” groups in small-cell and NSCLC patients. The findings suggest that the LabPS score not only contributes to prognostic classification but also has potential for predicting survival. Since the LabPS score can be easily integrated with routine laboratory tests and clinical parameters such as PS, it stands out as a potential clinical utility in daily practice. There is a need for prospective studies with larger sample sizes, but if validated in future studies, this score may assist in deciding the timing of chemotherapy and radiotherapy combinations, in dose optimization processes for thoracic radiotherapy, and in developing patient-specific treatment strategies. Furthermore, it is suggested that investigating the etiology of abnormalities in the laboratory parameters that affect the LabPS score and ensuring these values are returned to normal could help indirectly increase survival.
Author contributions
Conceptualization: Ozlem Elmas, Muslime Alp Karagedik, Bekir Hakan Bakkal.
Methodology: Ozlem Elmas, Muslime Alp Karagedik.
Data curation: Ozlem Elmas, Furuzan Kokturk.
Formal analysis: Furuzan Kokturk.
Investigation: Ozlem Elmas, Muslime Alp Karagedik.
Project administration: Ozlem Elmas.
Resources: Ozlem Elmas.
Writing – original draft: Ozlem Elmas, Muslime Alp Karagedik, Bekir Hakan Bakkal.
Writing – review & editing: Ozlem Elmas, Muslime Alp Karagedik.
Abbreviations:
- CI
- confidence interval
- CRP
- C-reactive protein
- ECOG
- Eastern Cooperative Oncology Group
- HR
- hazard ratio
- LabPS
- laboratory parameters + performance status
- LDH
- lactate dehydrogenase
- MFS
- metastasis-free survival
- NSCLC
- non-small-cell lung cancer
- OS
- overall survival
- PFS
- progression-free survival
- PS
- performance status
- RFS
- recurrence-free survival
- SCLC
- small-cell lung cancer
- TNM
- Tumor, Node, Metastasis classification
The study has been approved by the Zonguldak Bulent Ecevit University Faculty of Medicine’s Ethics Committee.
The authors have no funding and conflicts of interest to disclose.
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
How to cite this article: Elmas O, Alp Karagedik M, Bakkal BH, Kokturk F. Predictive value of a clinical score for overall survival following curative radiotherapy for lung cancer. Medicine 2026;105:25(e49314).
Contributor Information
Muslime Alp Karagedik, Email: alp.muslime@gmail.com.
Bekir Hakan Bakkal, Email: bhbakkal@beun.edu.tr.
Furuzan Kokturk, Email: fakokturk@gmail.com.
References
- [1].Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25:35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [2].Han S, Huang Y, Li Z, Hou H, Wu A. The prognostic role of preoperative serum albumin levels in glioblastoma patients. BMC Cancer. 2015;15:108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer. Medicine (Baltimore). 2019;98:e16238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Berghoff AS, Wolpert F, Holland-Letz T, et al. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol. 2017;19:1255–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Nieder C, Haukland EC, Mannsåker B, Dalhaug A. The LabPS score: inexpensive, fast, and site-agnostic survival prediction. Am J Clin Oncol. 2023;46:178–82. [DOI] [PubMed] [Google Scholar]
- [7].Taylor M, Abah U, Hayes T, et al. Preoperative anemia is associated with worse long-term survival after lung cancer resection: a multicenter cohort study of 5,029 patients. J Cardiothorac Vasc Anesth. 2022;36:1373–9. [DOI] [PubMed] [Google Scholar]
- [8].Dall’Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95–104. [DOI] [PubMed] [Google Scholar]
- [9].Min Y, Li X, Chen H, Xu Y, Lan G. Predicting outcomes of lung cancer using the modified Glasgow Prognostic Score: a systematic review and meta-analysis. Pak J Med Sci. 2024;40:534–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Wang YS, Niu L, Shi WX, Li XY, Shen L. Naples prognostic score as a predictor of outcomes in lung cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2023;27:8144–53. [DOI] [PubMed] [Google Scholar]
- [11].Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic significance of the Royal Marsden Hospital (RMH) score in patients with cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16:1835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Zhang X, Guo M, Fan J, et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark. 2016;16:415–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Richlitzki C, Wiesweg M, Metzenmacher M, et al. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy. Sci Rep. 2024;14:13765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Stensvold AM, Aggerholm-Pedersen N, Winther-Larsen A, Sandfeld-Paulsen B. Pre-treatment C-reactive protein predicts survival in small cell lung cancer patients. Onco. 2021;1:114–22. [Google Scholar]




